Is this the first disease-modifying treatment for endometriosis? Endometriosis is still largely managed with pain relief, hormones, and surgery, but a new precision peptide therapy seeks to directly target the underlying lesion biology. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/is-this-the-first-disease-modifying-treatment-for-endometriosis-17177?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8kBjsoZdS8P1xneMY7Oy7YU59cBZ-UVz3nQJhgPCT899eLAn3QL_Ugh4hRRXaHWcMY4aYQIvE7Z0D5ZGYIrAIv7PSwFw&_hsmi=421891039&utm_content=421891039&utm_source=hs_email After visiting 10 doctors in New York City, Tanya Petrossian was told she had ovarian cancer. She moved back to California to be close to her family, preparing for surgery and the possibility that her life was about to change permanently

Experimental gel could become the first approved treatment for cancer wounds Phase 2 trial shows that a topical drug rapidly reduces malodor, pain, and improves quality of life for patients with malignant fungating wounds. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/experimental-gel-could-become-the-first-approved-treatment-for-cancer-wounds-16906?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9m3w8PWxf50muvPP9_UnJwzU-L3vM7r7ZxxUAr_3Rt-q8ORWzbTHPqmwPRT-lWTemWaJ6OTC9XDDfOkLuQUjp2pkqkTg&_hsmi=421891039&utm_content=421891039&utm_source=hs_email In December 2025, Vyome Therapeutics announced compelling Phase 2 results for VT-1953, its investigational topical immunomodulator, in patients with malignant fungating wounds (MFWs) — a rare but highly distressing complication that affects an estimated five to 14 percent of individuals with advanced cancer.

The new drug compound that could treat measles outbreaks – and other viruses Researchers developed a highly-tolerable oral antiviral against orthoparamyxoviruses like measles and human parainfluenza virus types 1 and 3. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/the-new-drug-compound-that-could-treat-measles-outbreaks-and-other-viruses-17203 The viruses that make up the orthoparamyxovirus subfamily — which includes the reemerging measles virus, the highly-lethal Nipah virus, and human parainfluenza virus types 1 and 3 (HPIV1 and HPIV3) that cause high mortality in vulnerable stem cell transplant patients — are extremely contagious and largely have no approved antiviral treatments.

Cracking the Code: Optimizing Outcomes in All Patients With High-Risk HR+/HER2-Negative Early Breast Cancer Authors: Manali Bhave, MD; Shaheenah Dawood, MBBCh, MPH, FACP; Erika Hamilton, MD, FASCO

https://www.medscape.org/viewarticle/cracking-code-optimizing-outcomes-all-patients-high-risk-hr-2026a1000crj?page=3&uac=148436CN&src=mkmcmr_driv_il_mscpedu_260602_&subtitle-lang-code=es

Healthier Home | Huntington’s Disease | Memory and Aging | Food Tolerance | Wellness Toolkits

https://newsinhealth.nih.gov/

Short RNAs may prevent neuron death linked to ALS, dementia

Short RNAs may prevent neuron death linked to ALS, dementia At a Glance In cell and animal models, short RNA molecules stopped or reversed abnormal clumping of the TDP-43 protein, which is linked to brain cell death. The results suggest RNA-based therapies could one day be used to treat diseases marked by abnormal TDP-43, including ALS and Alzheimer’s disease. https://www.nih.gov/news-events/nih-research-matters/short-rnas-may-prevent-neuron-death-linked-als-dementia

Blood test predicts tumor response to treatment

Blood test predicts tumor response to treatment At a Glance Researchers identified distinct cellular neighborhoods common to different tumors, some of which correlate with treatment response. A blood test to analyze these neighborhoods could lead to more effective personalized cancer therapies and improve treatment monitoring and outcomes. https://www.nih.gov/news-events/nih-research-matters/blood-test-predicts-tumor-response-treatment